Brian Park, PharmD

Brian Park, PharmD

Drug Information Specialist https://www.empr.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Phase 3 Study Results Announced for Pregabalin in Primary Generalized Tonic-Clonic Seizures

A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to reduce seizure frequency compared with placebo, according to Pfizer. The 12-week randomized, double-blind, placebo-controlled, multicenter study was conducted at 70 sites in…

Revlimid Plus Rituximab Approved for Follicular Lymphoma, Marginal Zone Lymphoma

The Food and Drug Administration (FDA) has approved Revlimid (lenalidomide; Celgene) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL). The approval was based on the randomized, double-blind, phase 3 AUGMENT study that evaluated the efficacy and safety of Revlimid…

Selective Estrogen Receptor Modulators May Be Effective for Male Infertility

Selective estrogen receptor modulators (SERMs) may be effective for treating male infertility, according to a recent systematic review and meta-analysis published in Expert Opinion on Pharmacotherapy. SERMs are compounds that exhibit tissue-selective estrogen receptor agonist and antagonist activity. Clomiphene citrate and tamoxifen are two agents commonly used for the off-label management of male infertility. To…